A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma

BackgroundProgrammed cell death ligand 1 (PD-L1) inhibitors have limited efficacy as monotherapy in patients with recurrent/metastatic (R/M) Human Papilloma Virus (HPV) oropharyngeal squamous cell carcinoma (OPSCC). A phase I study of the therapeutic HPV-16 DNA vaccine AMV002 in curatively treated p...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Rahul Ladwa, Janin Chandra, Wai-Ping Woo, Neil Finlayson, Howard Liu, Margaret McGrath, Adrienne See, Brett G. Hughes, Caroline L. Cooper, Jim E. Jackson, Marcin Dzienis, Yan Xu, Benedict Panizza, Ian Frazer, Sandro V. Porceddu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-07-01
Rangatū:	Frontiers in Oncology
Ngā marau:	immune checkpoint inhibitor HPV - human papillomavirus HPV vaccination immunotherapies oropharangeal cancer
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1419258/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!